First-in-Class: FDA OKs Triple Therapy to Treat Hypertension

Hypertension, one of the most common chronic conditions, significantly increases the risk of cardiovascular diseases when poorly controlled. Current treatment guidelines recommend single-pill combination therapies for most patients to achieve effective BP management. Such combination drugs must balance efficacy with safety in clinical use.Widaplik is a fixed-dose combination tablet comprising three antihypertensive agents: telmisartan, amlodipine, and indapamide. These components work synergistically through distinct mechanisms to reduce peripheral vascular resistance and lower blood pressure:

Telmisartan, an angiotensin II receptor blocker (ARB), selectively inhibits the binding of angiotensin II to AT1 receptors, suppressing vasoconstriction and aldosterone release, thereby dilating blood vessels and reducing BP.

Amlodipine, a dihydropyridine calcium channel blocker (CCB), blocks calcium influx into vascular smooth muscle cells, relaxing vascular tone and directly dilating peripheral arterioles to reduce vascular resistance.

Indapamide, a thiazide-like diuretic, exerts both diuretic and vasodilatory effects.

Widaplik is available in three dosage strengths: 10/1.25/0.625 mg, 20/2.5/1.25 mg, and 40/5/2.5 mg. Its triple-mechanism action provides synergistic efficacy early in treatment, with clinical data confirming favorable safety and tolerability.

SZEB  specializes in providing high-quality reference standards for telmisartan, amlodipine, and indapamide-related impurities. These products support comprehensive impurity analysis and quality control, ensuring drug safety and compliance. For more information, visit our official website: www.ex-biotech.com or contact us by E-mail:sales@ex-biotech.com .

News Source:‘George Medicines announces FDA approval of WIDAPLIK™ (telmisartan, amlodipine and indapamide), a new single pill combination treatment for hypertension in adults, including initial treatment’.